Latest: FDA Approves New Biosimilar for Oncology Treatment
Neurology

Efgartigimod Meets End Point in Seronegative Myasthenia Gravis Study, Cemdisiran Submission for MG Coming Soon, Phase 3 Studies of IncobotulinumtoxinA Begin

by Neurology Live
0 Comments
0 Mins
Neurology News Network. for the week ending August 30, 2025. [WATCH TIME: 4 minutes]
Tags:
Neurology Live
Author

Neurology Live

Previous Post
Biogen, Eisai get USFDA nod for Leqembi Iqlik Subcutaneous Injection for maintenance dosing for early Alzheimer's Disease
Next Post
Smoking Remains a Major Driver of Rheumatoid Arthritis Burden Worldwide
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago